Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
Retrieved on:
화요일, 2월 27, 2024
Pharmaceutical, General Health, Professional Services, Women, Philanthropy, Hospitals, Teens, LGBTQ+, Fund Raising, Biotechnology, Science, DEI (Diversity, Equity and Inclusion), AIDS, Consumer, Research, Health, Woman, National Association, Gilead Sciences, Investment, Transgender, General counsel, Corporate Affairs, Organization, Health equity, Community, Ageing, HIV, Pharmaceutical industry
(Prevention, Arts and Advocacy, Community, Education) initiative, a three-year commitment toward increasing HIV prevention, anti-stigma and health equity efforts for Black cisgender and Transgender women and girls, who are disproportionately impacted by the HIV epidemic.
Key Points:
- (Prevention, Arts and Advocacy, Community, Education) initiative, a three-year commitment toward increasing HIV prevention, anti-stigma and health equity efforts for Black cisgender and Transgender women and girls, who are disproportionately impacted by the HIV epidemic.
- In 2021, Black women accounted for 53% of new HIV diagnoses among women aged 16 and older in the United States, despite comprising only 14% of the women living in the country.
- Additionally, Black Transgender women have the highest rates of new HIV diagnoses among Transgender people and are more likely to go undiagnosed and untreated in comparison to their peers.
- These inequities are exacerbated by significant gaps in the delivery of effective and culturally relevant HIV prevention information and care services for Black women and girls.